{"id":"methamphetamine-hydrochloride-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Nervousness/anxiety"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations/tachycardia"},{"rate":null,"effect":"Appetite suppression"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methamphetamine acts as a potent stimulant by promoting the release of catecholamines (dopamine and norepinephrine) from presynaptic neurons and inhibiting their reuptake, leading to increased synaptic concentrations. This mechanism results in enhanced central nervous system stimulation, increased wakefulness, improved attention, and appetite suppression. The drug crosses the blood-brain barrier readily due to its lipophilic nature, making it highly potent.","oneSentence":"Methamphetamine hydrochloride is a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing alertness and focus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:50.575Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"},{"name":"Exogenous obesity (historical indication, rarely used)"}]},"trialDetails":[{"nctId":"NCT06233799","phase":"PHASE3","title":"Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2024-07-01","conditions":"Methamphetamine-dependence, Methamphetamine Abuse","enrollment":360},{"nctId":"NCT03341078","phase":"PHASE2","title":"Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2019-05-01","conditions":"Methamphetamine-dependence","enrollment":176},{"nctId":"NCT06931197","phase":"NA","title":"Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization","status":"NOT_YET_RECRUITING","sponsor":"Queen's Medical Center","startDate":"2026-01-01","conditions":"Contingency Management, Methamphetamine Use Disorder","enrollment":20},{"nctId":"NCT04642820","phase":"EARLY_PHASE1","title":"Drugs Brain and Behavior (DDP)","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-11-01","conditions":"Stimulant Use","enrollment":138},{"nctId":"NCT03973489","phase":"PHASE4","title":"Effects of Genotype on Resting State Connectivity During Methamphetamine Administration","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2019-08-16","conditions":"Methamphetamine-dependence","enrollment":69},{"nctId":"NCT05379959","phase":"EARLY_PHASE1","title":"Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2022-05-11","conditions":"Stimulant Use, MDMA ('Ecstasy'), Social Behavior","enrollment":43},{"nctId":"NCT01217970","phase":"PHASE1","title":"Safety Interaction Trial Ibudilast and Methamphetamine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-01","conditions":"Methamphetamine-dependence, Substance Abuse","enrollment":11},{"nctId":"NCT00332605","phase":"PHASE2","title":"N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2006-06","conditions":"Methamphetamine Dependence","enrollment":45},{"nctId":"NCT00593905","phase":"","title":"Pharmacogenomics in Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"West Penn Allegheny Health System","startDate":"2005-07","conditions":"Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I","enrollment":""},{"nctId":"NCT03078075","phase":"PHASE3","title":"Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-05-05","conditions":"Methamphetamine Use Disorder","enrollment":403},{"nctId":"NCT00730522","phase":"PHASE2","title":"Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence","status":"TERMINATED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2008-07","conditions":"Methamphetamine Dependence","enrollment":55},{"nctId":"NCT03864653","phase":"NA","title":"Depression Intervention Among Gay and Bisexual Men Receiving Treatment for Methamphetamine Use","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2019-02-25","conditions":"HIV/AIDS, Methamphetamine Abuse, Depression","enrollment":39},{"nctId":"NCT03106571","phase":"PHASE1","title":"Study of Pomaglumetad and Methamphetamine","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2017-08-01","conditions":"Methamphetamine Use Disorder","enrollment":19},{"nctId":"NCT01982643","phase":"PHASE1, PHASE2","title":"Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder","status":"COMPLETED","sponsor":"Walter Ling","startDate":"2013-11","conditions":"Methamphetamine Use Disorder","enrollment":49},{"nctId":"NCT00751023","phase":"PHASE4","title":"Effects of Modafinil in Methamphetamine Dependence","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-02","conditions":"Methamphetamine Dependence","enrollment":40},{"nctId":"NCT02323048","phase":"NA","title":"Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07","conditions":"Substance Abuse","enrollment":90},{"nctId":"NCT01825928","phase":"NA","title":"An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence","status":"COMPLETED","sponsor":"Wei Hao","startDate":"2013-02","conditions":"Methamphetamine Dependence","enrollment":80},{"nctId":"NCT00520286","phase":"PHASE2","title":"Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2007-12","conditions":"Methamphetamine Dependence","enrollment":210},{"nctId":"NCT00345371","phase":"PHASE2","title":"Topiramate for the Treatment of Methamphetamine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2006-04","conditions":"Methamphetamine","enrollment":140},{"nctId":"NCT00687713","phase":"PHASE2","title":"Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2008-05","conditions":"Methamphetamine Dependence","enrollment":200},{"nctId":"NCT01822730","phase":"PHASE4","title":"A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"COMPLETED","sponsor":"Wei Hao","startDate":"2013-02","conditions":"Methamphetamine Dependence","enrollment":120},{"nctId":"NCT01651169","phase":"NA","title":"Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Attention Deficit Hyperactivity Disorder (ADHD)","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2012-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":30},{"nctId":"NCT01215929","phase":"PHASE2","title":"Studying Amphetamine Withdrawal in Humans","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2009-10","conditions":"Methamphetamine Dependence","enrollment":35},{"nctId":"NCT00833443","phase":"PHASE2","title":"Study of Medical Treatment for Methamphetamine Addiction","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-01","conditions":"Methamphetamine, Amphetamine Dependence, Pharmacogenetics","enrollment":84},{"nctId":"NCT01939093","phase":"PHASE4","title":"Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2010-03","conditions":"Methamphetamine-induced Psychosis","enrollment":80},{"nctId":"NCT00994448","phase":"PHASE2","title":"Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-10","conditions":"Adolescent Methamphetamine Abuse","enrollment":19},{"nctId":"NCT01011829","phase":"PHASE2","title":"Varenicline vs Placebo for the Treatment of Methamphetamine Dependence","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-11","conditions":"Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse","enrollment":20},{"nctId":"NCT01007539","phase":"PHASE3","title":"Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-11","conditions":"Methamphetamine Dependence","enrollment":31},{"nctId":"NCT00630097","phase":"PHASE2","title":"A Dose Ranging Study of Modafinil for Methamphetamine Dependence","status":"UNKNOWN","sponsor":"California Pacific Medical Center Research Institute","startDate":"2009-12","conditions":"Substance Dependence, Amphetamine Dependence","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Desoxyn"],"phase":"marketed","status":"active","brandName":"Methamphetamine Hydrochloride Tablets","genericName":"Methamphetamine Hydrochloride Tablets","companyName":"Oregon Health and Science University","companyId":"oregon-health-and-science-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methamphetamine hydrochloride is a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing alertness and focus. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy, Exogenous obesity (historical indication, rarely used).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}